van de Pol, Natasja
van der Woude, C. Janneke
Vis, Marijn
van Doorn, Martijn B.A.
Schrauwen, Saskia L.
Cetinözman-Teunissen, Fatos
West, Rachel L.
de Vries, Annemarie C.
Funding for this research was provided by:
Pfizer Pharmaceuticals (68985113)
Article History
Received: 26 April 2024
Accepted: 8 August 2024
First Online: 22 August 2024
Declarations
:
: This study was approved by the Institutional Review Board (IRB) of the EMC, MEC-2022-0196.
: CJW received grants from ZonMW, Falk and Pfizer, has received consulting fees from Janssen, Galapagos, and Pfizer, has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring and AbbVie and had leadership roles in the European Crohn’s & Colitis organisation, United European Gastroenterology council and the Dutch Association for Gastroenterology (NVGE); MV received research funding/advisory board fees from Novartis, UCB, Janssen, AbbVie, Lilly, and Pfizer; MBAvD reports grants and has served on the advisory board or as a speaker for Novartis and Janssen-Cilag. He has also has served on the advisory board or as a speaker for Abbvie, Leopharma, BMS, Celgene, Lilly, MSD, Pfizer, and Sanofi-Genzyme; RLW has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Ferring, Pfizer, Galapagos, AbbVie and Janssen; ACV has served on advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos and has received unrestricted research grants from Takeda, Janssen, and Pfizer; all other authors declare that they have no conflict of interest.